BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15947684)

  • 21. A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.
    Kanigel Winner KR; Costello JC
    Pac Symp Biocomput; 2017; 22():611-622. PubMed ID: 27897011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haematological toxicity in patients treated with cisplatin and gemcitabine for bladder cancer: the Weston Park Hospital, Sheffield, experience.
    Clenton SJ; Kirkbride P; Ferguson CJ
    Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):639. PubMed ID: 17051958
    [No Abstract]   [Full Text] [Related]  

  • 23. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.
    Türkölmez K; Bedük Y; Baltaci S; Göğüş C; Göğüş O
    Eur Urol; 2003 Dec; 44(6):682-6. PubMed ID: 14644120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
    von der Maase H
    Eur J Cancer; 2000 Jul; 36 Suppl 2():13-6. PubMed ID: 10908843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer].
    Bodrogi I
    Magy Onkol; 2003; 47(2):198-203. PubMed ID: 12975670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
    Song YS; Cho JS; Cho KS; Doo SH; Chung BH; Kim SJ; Yang WJ; Song KH; Kim CI; Hong SJ
    Urol Int; 2010; 85(1):47-51. PubMed ID: 20234122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
    Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
    J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
    Gross-Goupil M; Domblides C; Lefort F; Ravaud A
    Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
    van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
    World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.
    Miyake H; Eto H; Hara I; So A; Li D; Gleave ME
    J Urol; 2004 Jun; 171(6 Pt 1):2477-81. PubMed ID: 15126879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
    Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
    Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
    Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
    Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
    Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
    Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
    Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
    Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
    J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
    Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
    Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.
    Stadler WM; Hayden A; von der Maase H; Roychowdhury D; Dogliotti L; Seymour L; Kaufmann D; Moore M
    Urol Oncol; 2002; 7(4):153-7. PubMed ID: 12474531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
    Halim A; Abotouk N
    Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
    Camargo EA; da Silva GN; Gobette CP; Marcondes JP; Salvadori DM
    Asian Pac J Cancer Prev; 2013; 14(10):5941-8. PubMed ID: 24289605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
    Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
    Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.